CY1118920T1 - Ενωσεις πιπεραζινης- πιπεριδινης ως αναστολεις του ιου ηπατιτιδας c - Google Patents

Ενωσεις πιπεραζινης- πιπεριδινης ως αναστολεις του ιου ηπατιτιδας c

Info

Publication number
CY1118920T1
CY1118920T1 CY20171100520T CY171100520T CY1118920T1 CY 1118920 T1 CY1118920 T1 CY 1118920T1 CY 20171100520 T CY20171100520 T CY 20171100520T CY 171100520 T CY171100520 T CY 171100520T CY 1118920 T1 CY1118920 T1 CY 1118920T1
Authority
CY
Cyprus
Prior art keywords
compounds
virus
inhibitors
piperazine
piperidine compounds
Prior art date
Application number
CY20171100520T
Other languages
Greek (el)
English (en)
Inventor
Daniel D Long
Robert Murray Mckinnell
Orden Lori Jean Van
Gavin Ogawa
Donna Wilton
Original Assignee
Theravance Biopharma R&D Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip, Llc filed Critical Theravance Biopharma R&D Ip, Llc
Publication of CY1118920T1 publication Critical patent/CY1118920T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
CY20171100520T 2012-04-25 2017-05-17 Ενωσεις πιπεραζινης- πιπεριδινης ως αναστολεις του ιου ηπατιτιδας c CY1118920T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261637959P 2012-04-25 2012-04-25
US201361774033P 2013-03-07 2013-03-07
PCT/US2013/037920 WO2013163262A1 (en) 2012-04-25 2013-04-24 Piperazine-piperidine compounds as hepatitis c virus inhibitors

Publications (1)

Publication Number Publication Date
CY1118920T1 true CY1118920T1 (el) 2018-01-10

Family

ID=48237291

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100520T CY1118920T1 (el) 2012-04-25 2017-05-17 Ενωσεις πιπεραζινης- πιπεριδινης ως αναστολεις του ιου ηπατιτιδας c

Country Status (17)

Country Link
US (1) US9206159B2 (cg-RX-API-DMAC10.html)
EP (1) EP2850075B1 (cg-RX-API-DMAC10.html)
JP (1) JP6069491B2 (cg-RX-API-DMAC10.html)
CN (1) CN104302639B (cg-RX-API-DMAC10.html)
CA (1) CA2869640C (cg-RX-API-DMAC10.html)
CY (1) CY1118920T1 (cg-RX-API-DMAC10.html)
DK (1) DK2850075T3 (cg-RX-API-DMAC10.html)
ES (1) ES2624846T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20170471T1 (cg-RX-API-DMAC10.html)
HU (1) HUE032173T2 (cg-RX-API-DMAC10.html)
LT (1) LT2850075T (cg-RX-API-DMAC10.html)
ME (1) ME02682B (cg-RX-API-DMAC10.html)
PL (1) PL2850075T3 (cg-RX-API-DMAC10.html)
PT (1) PT2850075T (cg-RX-API-DMAC10.html)
RS (1) RS55864B1 (cg-RX-API-DMAC10.html)
SI (1) SI2850075T1 (cg-RX-API-DMAC10.html)
WO (1) WO2013163262A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108794454B (zh) * 2017-04-27 2023-08-15 广东东阳光药业股份有限公司 一种咪唑环化合物的制备方法
CN112480084B (zh) * 2017-11-27 2021-09-21 常州寅盛药业有限公司 反应路线简单的达卡他韦起始原料的合成方法
EP4759807A1 (en) 2023-08-11 2026-06-17 Shenzhen Zhongge Biological Technology Co., Ltd. Proteolysis targeting chimera compound for degrading irak4 and use thereof
CN122497677A (zh) 2023-10-20 2026-07-31 奇树医药公司 一种降解irak4的蛋白降解靶向嵌合体化合物及其应用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007115805A2 (en) * 2006-04-05 2007-10-18 European Molecular Biology Laboratory (Embl) Aurora kinase inhibitors
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8303944B2 (en) 2006-08-11 2012-11-06 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7659270B2 (en) 2006-08-11 2010-02-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8147818B2 (en) 2008-02-13 2012-04-03 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20120040977A1 (en) 2009-02-23 2012-02-16 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2010094977A1 (en) 2009-02-23 2010-08-26 Arrow Therapeutics Limited Novel biphenyl compounds useful for the treatment of hepatitis c
US8796466B2 (en) 2009-03-30 2014-08-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
SG176015A1 (en) 2009-05-13 2011-12-29 Gilead Sciences Inc Antiviral compounds
EP2473056A4 (en) 2009-09-04 2013-02-13 Glaxosmithkline Llc CHEMICAL COMPOUNDS
US8822700B2 (en) 2009-09-11 2014-09-02 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
WO2011031904A1 (en) 2009-09-11 2011-03-17 Enanta Pharmaceuticals, Inc Hepatitis c virus inhibitors
EP2475254A4 (en) * 2009-09-11 2013-05-22 Enanta Pharm Inc HEPATITIS C-VIRUS HEMMER
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US8653070B2 (en) 2009-12-14 2014-02-18 Enanta Pharmaceuticals, Inc. Hepatitis C virus inhibitors
US8377980B2 (en) 2009-12-16 2013-02-19 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CN102883718A (zh) 2009-12-24 2013-01-16 顶点制药公司 用于治疗或预防黄病毒感染的类似物
WO2011091446A1 (en) 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
MA34147B1 (fr) 2010-03-09 2013-04-03 Merck Sharp & Dohme Composes tricycliques fusionnes de silyle et leurs methodes d'utilisation dans le cadre du traitement de maladies virales
EP2575819A4 (en) 2010-06-04 2013-11-27 Enanta Pharm Inc INHIBITORS OF HEPATITIS C VIRUS
US20120195857A1 (en) 2010-08-12 2012-08-02 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2012048421A1 (en) 2010-10-14 2012-04-19 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
CA2814534A1 (en) 2010-11-04 2012-05-10 Theravance, Inc. Novel inhibitors of hepatitis c virus
US8552047B2 (en) 2011-02-07 2013-10-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
AR088630A1 (es) 2011-11-03 2014-06-25 Theravance Inc Inhibidores del virus de la hepatitis c
CA2869908C (en) * 2012-04-25 2018-02-20 Theravance Biopharma R&D Ip, Llc Hepatitis c virus inhibitors

Also Published As

Publication number Publication date
ES2624846T3 (es) 2017-07-17
ME02682B (me) 2017-06-20
CA2869640A1 (en) 2013-10-31
SI2850075T1 (sl) 2017-06-30
WO2013163262A1 (en) 2013-10-31
HUE032173T2 (en) 2017-09-28
EP2850075B1 (en) 2017-02-22
CA2869640C (en) 2018-03-20
DK2850075T3 (en) 2017-05-22
CN104302639B (zh) 2017-03-29
CN104302639A (zh) 2015-01-21
JP6069491B2 (ja) 2017-02-01
US20130287730A1 (en) 2013-10-31
PT2850075T (pt) 2017-05-02
HRP20170471T1 (hr) 2017-06-02
EP2850075A1 (en) 2015-03-25
PL2850075T3 (pl) 2017-08-31
JP2015514807A (ja) 2015-05-21
LT2850075T (lt) 2017-05-10
US9206159B2 (en) 2015-12-08
RS55864B1 (sr) 2017-08-31

Similar Documents

Publication Publication Date Title
CY1126771T1 (el) Συνδυασμοι δολουτεγραβιρης και λαμιβουδινης για την αγωγη λοιμωξης απο hiv
CY1122279T1 (el) Ενωσεις ναφθυριδινης αναστολεις κινασης jak
CY1121418T1 (el) Παρεμποδιστες ιου ηπατιτιδας c
CY1123324T1 (el) Παραγωγα πυριμιδινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων
CY1121706T1 (el) Ενωσεις υποκατασταθεισες διυδροϊσοκινολινονης
CY1121972T1 (el) Mono- ή διυποκατεστημενα ινδολια ως αναστολεις του αναδιπλασιασμου του ιου του δαγκειου πυρετου
PH12015501881B1 (en) Amide compounds for the treatment of hiv
NZ729150A (en) Antiretroviral agents
MX347692B (es) Inhibidores del virus de la hepatitis c.
NZ631726A (en) Therapeutic compounds for the treatment of viral infections
CY1119620T1 (el) Αναστολεις νεπριλυσινης
CY1121874T1 (el) Παραγωγα μονο- ή διυποκατεστημενου ινδολιου ως αναστολεις του αναδιπλασιασμου του ιου του δαγκειου πυρετου
BR112014030639A2 (pt) inibidores macrocíclicos de vírus flaviviridae
BR112014030630A2 (pt) inibidores macrocíclicos de vírus flaviviridae
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
NZ631738A (en) (hetero) arylacetamide derivatives as antiretroviral agents
MX2017001862A (es) Nuevas piridazonas y triazinonas para el tratamiento y la profilaxis de infeccion por virus de hepatitis b.
CY1117105T1 (el) Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao
EA201791776A1 (ru) Замещенные циклофаны для использования при лечении инфекции вгс
CY1121063T1 (el) Αναστολεις της συνθασης της αλδοστερονης
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
CY1121650T1 (el) Αναστολεις συνθασης αλδοστερονης
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
EA201490213A1 (ru) Бензофурановые соединения для лечения инфекций вирусом гепатита с
MX379015B (es) Inhibidores de la polimerasa del virus de la hepatitis c.